We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Weight‐adapted fixed‐dose combined adult antiretroviral tablets for HIV‐infected children.
- Authors
Bossacoma Busquets, Ferran; Sánchez, Emilia; Noguera‐Julián, Antoni; Villaronga Flaqué, Miquel; Fortuny, Clàudia
- Abstract
What is known and objective: Therapeutic alternatives to simplify antiretroviral therapy (ART) in HIV‐infected children are needed. We report our experience with abacavir(ABC)/lamivudine(3TC) individualized dose compounded capsules (IDCC). Comment: We present a prospective case series of HIV‐infected children who did not weigh enough to receive the adult fixed‐dose combination including ABC/3TC 600mg/300mg, and were treated with weight‐adapted ABC/3TC IDCC in Barcelona, Spain. Thirteen patients (12 girls) received ABC/3TC IDCC for a median(IQR) time of 30(17‐54) months. No significant changes were observed in CD4 cell counts, weight or height z‐scores over time. Suppression of viral replication was maintained in 7 patients with undetectable viremia at baseline. Another 5 patients achieved viral suppression with ABC/3TC IDCC‐based ART, while one non‐adherent girl did not. No adverse events related to ABC/3TC IDCC were observed. What is new and conclusion: Despite small numbers, the long‐term use of ABC/3TC IDCC was feasible, safe, and effective in the treatment of HIV‐infected children.
- Subjects
SPAIN; HIV infections; VIRAL physiology; COMBINATION drug therapy; VIRAL load; ANTIRETROVIRAL agents; INDIVIDUALIZED medicine; LAMIVUDINE; DESCRIPTIVE statistics; ABACAVIR; LONGITUDINAL method; CHILDREN
- Publication
Journal of Clinical Pharmacy & Therapeutics, 2021, Vol 46, Issue 4, p867
- ISSN
0269-4727
- Publication type
Article
- DOI
10.1111/jcpt.13341